

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.*

*This announcement is not, and does not form any part of, an offer or invitation for the sale of securities in the United States (including its territories and dependencies, any State of the United States and the District of Columbia). Neither this announcement nor anything herein nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States. The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”) or any other applicable securities laws of the United States, and may not be offered, sold or otherwise transferred within the United States unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act or any other applicable securities laws of the United States is available. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and will contain detailed information about the Company and management, as well as financial statements. The Company does not intend to make any public offering of securities in the United States.*



**RemeGen Co., Ltd.\***

**榮昌生物製藥(煙台)股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 9995)**

## **COMPLETION OF PLACING OF H SHARES**

**Overall Coordinators and Placing Agents**

**Morgan Stanley**



The Board is pleased to announce that completion of the Placing took place on May 29, 2025 in accordance with the terms and conditions of the Placing Agreement. All conditions precedent to the Placing as set out in the Placing Agreement have been satisfied.

Reference is made to the announcement of RemeGen Co., Ltd. (the “**Company**”) dated May 22, 2025 (the “**Announcement**”) in relation to the placement of 19,000,000 new H Shares (the “**Placing**”). Unless otherwise defined, all capitalized terms used herein shall have the same meanings as those defined in the Announcement.

## **COMPLETION OF THE PLACING**

The Board is pleased to announce that all conditions precedent to the Placing, as set out in the Placing Agreement, have been satisfied (including the obtaining of approval for the listing of, and permission to deal in, the Placing Shares from the Listing Committee), and completion of the Placing took place on May 29, 2025 (the “**Completion**”).

An aggregate of 19,000,000 new H Shares, representing approximately 9.11% of the total number of issued H Shares and approximately 3.37% of the number of total issued Shares, in each case, as enlarged by the allotment and issue of the Placing Shares, have been successfully allotted and issued by the Company on May 29, 2025 at the placing price of HK\$42.44 per Placing Share to not less than six Placees, who and whose ultimate beneficial owners are third parties independent of and not connected with the Company, connected persons of the Company and any of the Directors, supervisors, chief executive or substantial shareholder(s) of the Company or any of its subsidiaries or their respective associates.

## **CHANGE OF SHARE CAPITAL UPON COMPLETION OF THE PLACING**

The number of total issued Shares has increased from 544,608,243 Shares to 563,608,243 Shares as a result of the issue of the Placing Shares. The number of total issued H Shares has increased from 189,581,239 H Shares to 208,581,239 H Shares upon Completion, and the number of A Shares remains unchanged as 355,027,004 A Shares.

The shareholding structure of the Company immediately before and after the Completion is as follows:

| Shareholder                  | Immediately before the Completion |   | Immediately after the Completion |   |
|------------------------------|-----------------------------------|---|----------------------------------|---|
|                              | <i>Number of<br/>Shares</i>       | <i>% of the<br/>total issued<br/>Shares</i> | <i>Number of<br/>Shares</i>      | <i>% of the<br/>total issued<br/>Shares</i> |
| <b>A SHARES</b>              |                                   |   |                                  |   |
| <b>Total issued A Shares</b> | <b>355,027,004</b>                | <b>65.19</b>                                | <b>355,027,004</b>               | <b>62.99</b>                                |
| <b>H SHARES</b>              |                                   |   |                                  |   |
| Placees                      | –                                 | –   | 19,000,000                       | 3.37  |
| Core connected person(s)     | 24,569,041                        | 4.51  | 24,569,041                       | 4.36  |
| Public H Shares Shareholders | 165,012,198                       | 30.30                                       | 165,012,198                      | 29.28                                       |
| <b>Total issued H Shares</b> | <b>189,581,239</b>                | <b>34.81</b>                                | <b>208,581,239</b>               | <b>37.01</b>                                |
| <b>TOTAL ISSUED SHARES</b>   | <b>544,608,243</b>                | <b>100</b>                                  | <b>563,608,243</b>               | <b>100</b>                                  |

*Notes: The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.*

## USE OF PROCEEDS

As disclosed in the Announcement, on the assumption that all Placing Shares are fully placed, the aggregate gross proceeds from the Placing are expected to be HK\$806.36 million and the aggregate net proceeds (after deduction of the commissions and estimated expenses) from the Placing are expected to be approximately HK\$796 million.

The Placing has been fully placed. 90% of the net proceeds from the Placing (or HK\$716.4 million) are intended to be used by the Group to invest in research and development of its core product, Telitacicept (RC18) and for the expansion of its core indications (such as Myasthenia Gravis and Membranous Nephritis), which is expected to be fully utilized by December 31, 2027, and 10% of the net proceeds from the Placing (or HK\$79.6 million) are intended to be used for general corporate purposes, which is expected to be fully utilized by December 31, 2025.

Please refer to the Announcement for further details of the Placing.

By Order of the Board  
**RemeGen Co., Ltd.\***  
**Mr. Wang Weidong**  
*Chairman and executive director*

Yantai, PRC, May 29, 2025

*As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive Directors.*

\* For identification purpose only